RecruitingBreast CancerBreast Cancer - FemaleBreast Carcinoma
Supporting Health Including Endocrine Treatment for Long Duration
Eligible age
18–49 yrs
Accepts
Women
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This research is being done to pilot an intervention which aims to test a new web- and mobile application ("app")-based supportive care tool (SHIELD portal) and to assess the feasibility of enrolling female breast cancer patients with hormone receptor-positive disease long-term endocrine treatment.
Sponsor: Dana-Farber Cancer Institute
You may qualify if…
- ✓ Participants will be eligible if they meet the following eligibility criteria:
- ✓ Female
- ✓ Age 18-49 years at diagnosis of a stage 0-IIIa, HR+ breast cancer
- ✓ Premenopausal
- ✓ In active treatment (including long-term endocrine therapy) at the time of enrollment
- ✓ Able to speak, understand and read English
- ✓ Access to a US-based mobile phone number
- ✓ Cognitively able to complete study requirements
You may not qualify if…
- ✕ Participants will be ineligible if they meet any of the following criteria:
- ✕ Individuals under age 18 or over age 50 at initial breast cancer diagnosis
- ✕ Stage IV or metastatic breast cancer
- ✕ Pregnant patients
- ✕ Individuals who do not have a US mobile phone number
- ✕ Males with breast cancer are not being recruited to this protocol. In the adolescent and young adult (AYA) age group, only a miniscule proportion of breast cancers occur in males. Additionally, this pilot focuses on breast cancer treatment utilizing OFS and ET, both of which do not apply to males. For this reason, the SHIELD portal intervention materials have been targeted for young women.
Where it's recruiting
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT07482384 · last updated 2026-08-10